Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates [Yahoo! Finance]
Regulus Therapeutics Inc. (RGLS)
Last regulus therapeutics inc. earnings: 3/12 04:37 pm
Check Earnings Report
US:NASDAQ Investor Relations:
regulusrx.com/investors
Company Research
Source: Yahoo! Finance
Oversubscribed $100 million private placement; expected to extend cash runway into H1 2026 Completed enrollment of the third cohort of patients in the MAD study; Data anticipated mid-2024 Completed Type D Meeting with FDA to Discuss Pathway for Accelerated Approval of RGLS8429 SAN DIEGO March 21, 2024 /PRNewswire/ -- Regulus Therapeutics Inc (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2023 , and provided a corporate update. "2023 was a productive year for Regulus, and the growing momentum in our Phase 1b MAD study of RGLS8429 is further emphasized by our announcement of key milestones and data readouts, including the recent positive topline data from the second cohort of patients. In the topline data, we saw evidence of a mechanistic dose response at a 2 mg/kg dose level based on
Show less
Read more
Impact Snapshot
Event Time:
RGLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGLS alerts
High impacting Regulus Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
RGLS
News
- Global Antisense and RNAi Therapeutics Report 2024: A USD 34.7 Billion Predicted Market by 2034, with CAGR of 18% During 2024-2034 [Yahoo! Finance]Yahoo! Finance
- Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD [Seeking Alpha]Seeking Alpha
- Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
RGLS
Earnings
- 11/9/23 - Miss
RGLS
Sec Filings
- 4/22/24 - Form EFFECT
- 4/19/24 - Form ARS
- 4/19/24 - Form DEF
- RGLS's page on the SEC website